Abstract The National Cancer Institute Genomic Data Commons (GDC) is an information
system for storing, analyzing, and sharing genomic and clinical data from patients with …

Acute myeloid leukemia (AML) is a hematopoietic malignancy with poor prognosis and
limited treatment options. Here we provide a comprehensive census of the bone marrow …

Acute myeloid leukemia (AML) is a heterogeneous disease that is characterized by distinct
cytogenetic or genetic abnormalities. Recent discoveries in cancer epigenetics …

We present the molecular landscape of pediatric acute myeloid leukemia (AML) and
characterize nearly 1,000 participants in Children's Oncology Group (COG) AML trials. The …

Background As consolidation therapy for acute myeloid leukemia (AML), allogeneic
hematopoietic stem-cell transplantation provides a benefit in part by means of an immune …

Acute myeloid leukemia (AML) is a molecularly and clinically heterogeneous hematological
malignancy. Although immunotherapy may be an attractive modality to exploit in patients …

Acute myeloid leukemia (AML) comprises a heterogeneous group of leukemias frequently
defined by recurrent cytogenetic abnormalities, including rearrangements involving the core …

Mutations in the gene encoding isocitrate dehydrogenase 2 (IDH2) occur in several types of
cancer, including acute myeloid leukemia (AML). In model systems, mutant IDH2 causes …

Over the past decades, consistent studies have shown that race/ethnicity have a great
impact on cancer incidence, survival, drug response, molecular pathways and epigenetics …

The genetics of relapsed pediatric acute myeloid leukemia (AML) has yet to be
comprehensively defined. Here, we present the spectrum of genomic alterations in 136 …